Figure S3 from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer
Year: 2023
Type: other
Abstract: Supplemental Figure 3. Tumor volumes (TV; mean +/- SEM) over time of PDX DFCI 359 and PDX 315 dosed with neratinib (40mg/kg daily), TDM1 (20 mg/kg weekly), and their combinations (n = 8 mice/cohort). The data for the vehicle and neratinib arms for DFCI 315 are from the same experiment as in Figure 5D.
Authors: Elena Ivanova, Mari Kuraguchi, Man Xu, Andrew J. Portell, Luke Taus, Irmina Diala, Alshad S. Lalani, Jihyun Choi, Emily S. Chambers, Shuai Li, Shengwu Liu, Ting Chen, Thanh U. Barbie, Geoffrey R. Oxnard, Jacob J. Haworth, Kwok-Kin Wong, Suzanne E. Dahlberg, Amir A. Aref, David A. Barbie, Magda Bahcall, Cloud P. Paweletz, Pasi A. Jänne
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361934834